Author

C. Ball

Observed name: C Ball

Institutions: The University of Melbourne, Peter MacCallum Cancer Centre, King Edward Memorial Hospital, Women and Infants Research Foundation

Observed institutions: Cedars-Sinai Medical Center, The University of Melbourne, Peter MacCallum Cancer Centre, King Edward Memorial Hospital, Women and Infants Research Foundation, St John of God Health Care

OpenAlex ID: A5111550837

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

2018 · Olga Kondrashova, Monique Topp, et al. · Nature Communications · 298

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

2020 · Eun Young Kang, Dane Cheasley, et al. · Modern Pathology · 42

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance

2024 · Ksenija Nesic, John J. Krais, et al. · Molecular Cancer · 36

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

2018 · Matthew S. Block, Robert A. Vierkant, et al. · Mayo Clinic Proceedings · 31

Timing of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer

2024 · Nikki L. Burdett, Madelynne O. Willis, et al. · Nature Communications · 16

Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci

2022 · Amber A DeVries, Joe Dennis, et al. · JNCI Journal of the National Cancer Institute · 12

Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer

2023 · Nikki L. Burdett, Madelynne O. Willis, et al. · Scientific Reports · 6

Works count: 7

Citation count: 441

H-index: 6

I10-index: 6